National Institute of Allergy and Infectious Diseases (NIAID)

140 Protocols (106 Active Accrual of new subjects, 34 Follow-up of previously enrolled subjects)

 87-I-0163:

Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies

 85-I-0127:

Treatment of Patients with Cysticercosis with Praziquantel, Albendazole and Other Novel Treatment Modalities

 82-I-0183:

Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut

 81-I-0164:

Apheresis Procedures to Obtain Plasma or Lymphocytes for In Vitro Studies

 78-I-0023:

Diagnosis and Management of Inflammatory and Infectious Diseases

 77-I-0094:

Study of Patients with Parasitic Infections of the Gastrointestinal Tract

 07-I-0172:

A Phase I Open-Label Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for the Influenza Virus H5 Hemagglutinin Protein Administered Intradermally in Healthy Adults

 07-I-0155:

A Ph I/IIa Rand Placebo Ctrl, S-Blind Multictr Dose-Esc Study of SC Intermittent Interleukin-7 CYT107 in Chronically HIV-Infected Pts with CD4 T Lymphocyte Counts 101-400 Cells-/mm(3) and Plasma HIV RNA Less Than 50 copies/mL After at Least 12 M of HAART

 07-I-0094:

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

 07-I-0083:

Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria

 06-I-0237:

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults

 06-I-0180:

Evaluation of Alternative Oseltamivir (Tamiflu[R]) Dosing Strategies for Use during Influenza Prophylaxis

 06-I-0149:

VRC 011: A Phase I Clinical Trial of Intramuscular, Subcutaneous and Intradermal Administration of an HIV-1 Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, and an HIV-1 Multiclade Adenoviral Vector Vaccine,VRC-HIVADV014-00-VP, in Uninfected Adult Volunteer

 06-I-0105:

A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Intravenous Peramivir in Healthy Subjects

 06-I-0056:

VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine

 05-I-0133:

Phase 1 Study of the Safety of Immunization of Naive Individuals with AMA1-C1/Alhydrogel [R], an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria, and the Effect of Immunization on Antigen-specific Memory and Plasma B Cells and T Cells

 05-I-0127:

Assessing the Relationship Between Fatigue and Mitochondrial Toxicity in Patients with HIV/AIDS

 05-I-0123:

A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Participants w/HIV-1 Infection and CD4+ Cell Counts Greater Than or Equal to 300/mm(3)

 05-I-0065:

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Leflunomide on HIV-1 Associated Immune Proliferation In Vivo

 04-I-0289:

Secondary Transplantation Using Moderate Dose Busulfan as Conditioning for a Patient with Partial Reconstitution Post Initial Allogeneic Transplantation

 04-I-0266:

Collection of Peripheral Blood and Bone Marrow From Healthy Donors for Use in In Vitro Research

 04-I-0172:

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers

 04-I-0158:

A Multictr, Random, Dbl-Blnd, Placebo-Cntrld, Parallel Grp Ph III Study to Eval Corticosteroid-Reduction/Sparing Effects of Mepolizumab 750 mg IV in Subj w/HES, eval Efficacy/Safety of Mepolizumab in Controlling Clin Signs/Symptoms of HES over 9 Mos.

 04-I-0018:

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Anti-Retroviral Treatment in HIV Infected Patients with CD4 T-Lymphocyte Count Greater Than 500 Cells/mm(3) Who Have Received Anti-Retroviral

 03-I-0022:

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers

 01-I-0171:

Substudies of ESPRIT: ESPRIT Influenza Vaccine Substudy (FLUVAC) and ESPRIT Tetanus-Pneumococcal Vaccine Substudy (TEPVAC)

 01-I-0126:

A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)

 00-I-0163:

Persistence of Epstein-Barr Virus in Vivo

 00-I-0143:

Chemokine System Polymorphisms and Risk of Atherosclerosis (CAD)

 00-I-0110:

Analysis of HIV Genetic Variation in Patients Prior to Initiation of Highly Active Antiretroviral Therapy

 00-I-0071:

Randomized, Open-Label, Phase III, International Study of Recombinant IL-2 (Proleukin) in Pts. w/HIV-1 Infection and CD4 Cell Counts Greater than or Equal to 300 Cells/mm3: Eval of Subcutaneous Proleukin in Randomized International Trial (ESPIRIT)

 99-I-0149:

Analysis of the Occurrence of Perilesional Edema and Seizures in Patients With Inactive Cysticercosis

 99-I-0106:

Trial of Varicella Vaccine for the Prevention of Herpes Zoster and Its Complications

 99-I-0015:

Immunologic and Virologic Characterization of HIV-Infected Patients After Cessation of Highly Active Antiretroviral Therapy (HAART)

 97-I-0189:

Studies of Lymphocyte Kinetics Using Bromodeoxyuridine

 97-I-0166:

Polymorphism of the Herpes Simplex Virus Receptor

 97-I-0082:

Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication

 95-I-0134:

Gene Therapy Approach for Chronic Granulomatous Disease

 95-I-0072:

Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients with Known or Suspected HIV Infection

 94-I-0203:

Cytokine Expression in Allergic Asthma

Previous 100 Protocols

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/30/2009